Salvage therapeutic strategies for bacillus Calmette–Guerin failure
@article{Hassler2019SalvageTS, title={Salvage therapeutic strategies for bacillus Calmette–Guerin failure}, author={Melanie R. Hassler and Shahrokh Francois Shariat and Francesco Soria}, journal={Current Opinion in Urology}, year={2019}, volume={29}, pages={239–246} }
Purpose of review To give an overview of current options for conservative treatment of patients failing intravesical bacillus Calmette–Guerin (BCG) and to discuss emerging approaches with potential future clinical applications. Recent findings Radical cystectomy is the standard-of-care for patients failing BCG therapy. In patients unfit or unwilling to undergo surgery, salvage therapy options could be proposed with the aim to offer local cancer control and prevent progression to muscle-invasive…
9 Citations
Therapeutic management of Bacillus Calmette–Guerin refractory patients: a narrative review
- Medicine
- 2020
High risk bladder cancer (BC) patients who fail Bacillus Calmette–Guerin (BCG) therapy suffer from a challenging disease due to its molecular and clinical heterogeneity. The course of the disease…
Novel anticancer therapy in BCG unresponsive non-muscle-invasive bladder cancer
- Medicine, BiologyExpert review of anticancer therapy
- 2020
This review presents the topics of BCG unresponsive NMIBC; definition, prognosis, and further treatment options: immunotherapy, intravesical chemotherapy, gene therapy, and targeted individualized therapy.
Salvage Therapy for Non-muscle-invasive Bladder Cancer: Novel Intravesical Agents.
- Medicine, BiologyThe Urologic clinics of North America
- 2020
Current Therapy and Emerging Intravesical Agents to Treat Non-Muscle Invasive Bladder Cancer.
- MedicineHematology/oncology clinics of North America
- 2021
Sequential Gemcitabine plus Docetaxel Is the Standard Second-line Intravesical Therapy for Bacillus Calmette-Guérin-unresponsive Non-muscle invasive Bladder Cancer: Con.
- MedicineEuropean urology focus
- 2021
Prognostic value of albumin to globulin ratio in non-muscle-invasive bladder cancer
- MedicineWorld Journal of Urology
- 2021
Preoperative serum AGR levels independently predicted the risk of disease progression in patients with non-muscle-invasive bladder cancer and was not found to be associated with either RFS or PFS in NMIBC patients based on their EAU risk group.
[Improvement of vaccination activities in urology].
- MedicineDer Urologe. Ausg. A
- 2019
The importance of various aspects of vaccinations in urology are highlighted and the improvement of consultation techniques for vaccinations is focused on to increase the vaccination rate and acceptance in the future.
Verbesserung der Impftätigkeiten in der Urologie
- Der Urologe
- 2019
Effektive Impfstoffe gegen verschiedene urologisch wichtige Erkrankungen stehen seit Langem zur Verfügung, und dennoch sind generell die Impfaktivitäten in der Urologie unzureichend präsent. Folglich…
References
SHOWING 1-10 OF 64 REFERENCES
Experience with Sequential Intravesical Gemcitabine and Docetaxel as Salvage Therapy for Non-Muscle Invasive Bladder Cancer
- Medicine, BiologyCurrent Urology Reports
- 2016
A more in-depth report of the therapeutic strategy with sequential gemcitabine and docetaxel intravesical therapy for this treatment-refractory population and practical advice on the approach to this challenging patient population is provided.
Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer.
- MedicineThe Cochrane database of systematic reviews
- 2017
The potential for synergistic antitumour activity of interferon (IFN)-alpha (α) and BCG provides some rationale for combination therapy for people who do not tolerate or respond to standard-dose BCG therapy.
Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group.
- MedicineThe Journal of urology
- 2000
Valrubicin was effective and well tolerated in patients with carcinoma in situ of the bladder refractory to BCG therapy and delaying cystectomy while attempting salvage therapy with valRubicin does not pose an undue risk to most patients.
Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder.
- MedicineJournal of clinical oncology : official journal of the American Society of Clinical Oncology
- 2006
Gemcitabine has activity in a high-risk patient population and remains a viable option for some patients who refuse cystectomy and has been found to be effective in patients with superficial bladder cancer refractory or intolerant to intravesical BCG therapy.
Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Guérin therapy.
- MedicineThe Journal of urology
- 2013
Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non-muscle invasive bladder cancer.
- MedicineUrologic oncology
- 2014
Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin.
- MedicineUrologic oncology
- 2013
Impact of previous bacille Calmette-Guérin failure pattern on subsequent response to bacille Calmette-Guérin plus interferon intravesical therapy.
- Medicine, BiologyUrology
- 2008
SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guérin.
- MedicineThe Journal of urology
- 2013
Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin.
- MedicineThe Journal of urology
- 2009